** Cell therapy developer ProKidney's PROK.O shares dip ~10% in early morning trading
** BofA Global Research cuts stock rating to "underperform" from "neutral" and trims price objective to a Wall-Street low of $1 from $3
** Brokerage says the bearish rating is to reflect a more conservative peak sales outlook for REACT, the company's experimental cell therapy being tested as a treatment of diabetic chronic kidney disease (CKD)
** BofA sees REACT as a high-risk program, given limitations in its Phase 2 data, and remains cautious that PROK can significantly accelerate its expected Phase 3 timeline from the current target of Q3 2027
** Avg rating of six brokerages is "buy"; their median PT is $4.50, according to data compiled by LSEG
** Its stock has lost ~64% so far this year
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。